首页> 外文期刊>癌と化学療法 >Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report
【24h】

Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report

机译:在吉西他滨施用后扩大的局部晚期胰腺癌并对口腔TS-1作出反应 - 一个案例报告

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We administered oral TS-1 alone for locally advanced pancreatic cancer that did not respond to gemcitabine (GEM). A 56-year-old man was admitted to our hospital because of obstructive jaundice due to stage III pancreatic head cancer. We performed chemotherapy using GEM at a dose of 1,000 mg/m(2) after reduction of jaundice by PTCD and stenting. Once the tumor was reduced, enlargement was confirmed after 8 months, and cholangitis appeared due to stent obstruction. After PTCD and stenting (stent in stent) were performed again,we administered oral TS-1 alone at a dose of 100 mg/body. We achieved antitumor activity again using TS-1. It is suggested that TS-1 is a useful second-line agent for pancreatic cancer.
机译:我们单独给予口服TS-1,用于局部晚期的胰腺癌,没有对吉西他滨(宝石)反应。 由于III阶段胰腺头癌,这是一个56岁的男子因障碍而受到诊断。 我们在通过PTCD和支架减少黄疸后,使用1,000mg / m(2)的剂量进行化学疗法。 一旦肿瘤减少,8个月后确认扩大,并且由于支架阻塞而出现胆管炎。 在再次进行PTCD和支架(支架中的支架)后,我们单独给予口服TS-1,剂量为100mg /体。 我们使用TS-1再次实现了抗肿瘤活动。 建议TS-1是胰腺癌的有用的第二型剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号